Rie Sugimoto

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 320 citations

S-1 Versus Gemcitabine, Gastrointestinal Oncology, Medicine +7

Cloning and Characterization of the Hakata Antigen, a Member of the Ficolin/Opsonin p35 Lectin Family

Rie Sugimoto, Yoshiaki Yae, Mina Akaiwa et al. · Journal of Biological Chemistry · 1998 · 211 citations · Full text

Histocompatibility, Immunohematology, Laboratory Immunology +23

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

M. Ikeda, Satoshi Shimizu, Tosiya Sato et al. · Annals of Oncology · 2016 · 165 citations · Full text

Activation of Retinoic X Receptor and Peroxisome Proliferator-Activated Receptor–γ Inhibits Nitric Oxide and Tumor Necrosis Factor–α Production in Rat Kupffer Cells

Koutaro Uchimura, Makoto Nakamuta, Munechika Enjoji et al. · Hepatology · 2001 · 127 citations · Full text